383 related articles for article (PubMed ID: 17157458)
1. Dose-independent pharmacokinetics of clindamycin after intravenous and oral administration to rats: contribution of gastric first-pass effect to low bioavailability.
Yang SH; Lee MG
Int J Pharm; 2007 Mar; 332(1-2):17-23. PubMed ID: 17157458
[TBL] [Abstract][Full Text] [Related]
2. Dose-independent pharmacokinetics of ondansetron in rats: contribution of hepatic and intestinal first-pass effects to low bioavailability.
Yang SH; Lee MG
Biopharm Drug Dispos; 2008 Oct; 29(7):414-26. PubMed ID: 18697186
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a chemoprotective agent, 2-(allylthio)pyrazine, after intravenous and oral administration to rats: hepatic and gastric first-pass effects.
Han KS; Lee MG
Drug Metab Dispos; 1999 Feb; 27(2):221-6. PubMed ID: 9929506
[TBL] [Abstract][Full Text] [Related]
4. Hepatic and intestinal first-pass effects of oltipraz in rats.
Bae SK; Kim JW; Kim YH; Kim YG; Kim SG; Lee MG
Biopharm Drug Dispos; 2005 May; 26(4):129-34. PubMed ID: 15744718
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of L-FMAUS, a new antiviral agent, after intravenous and oral administration to rats: contribution of gastrointestinal first-pass effect to low bioavailability.
Chung HJ; Lee JH; Woo SJ; Park HK; Koo CH; Lee MG
Biopharm Drug Dispos; 2007 May; 28(4):187-97. PubMed ID: 17377948
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, blood partition and protein binding of DA-7867, a new oxazolidinone.
Bae SK; Chung WS; Kim EJ; Rhee JK; Kwon JW; Kim WB; Lee MG
Biopharm Drug Dispos; 2004 Apr; 25(3):127-35. PubMed ID: 15083501
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of DA-6034, an agent for inflammatory bowel disease, in rats and dogs: Contribution of intestinal first-pass effect to low bioavailability in rats.
Chung HJ; Choi YH; Choi HD; Jang JM; Shim HJ; Yoo M; Kwon JW; Lee MG
Eur J Pharm Sci; 2006 Mar; 27(4):363-74. PubMed ID: 16387482
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of sildenafil after intravenous and oral administration in rats: hepatic and intestinal first-pass effects.
Shin HS; Bae SK; Lee MG
Int J Pharm; 2006 Aug; 320(1-2):64-70. PubMed ID: 16730145
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability.
Lee JH; Lee MG
J Pharm Pharm Sci; 2007; 10(1):37-50. PubMed ID: 17498392
[TBL] [Abstract][Full Text] [Related]
10. Stability, blood partition, and pharmacokinetics of a new reversible proton pump inhibitor, YJA-20379-1.
Kim SH; Han KS; Choi WS; Chang MS; Lee MG
Res Commun Mol Pathol Pharmacol; 1997 Oct; 98(1):77-84. PubMed ID: 9434317
[TBL] [Abstract][Full Text] [Related]
11. Dose-independent pharmacokinetics of metformin in rats: Hepatic and gastrointestinal first-pass effects.
Choi YH; Kim SG; Lee MG
J Pharm Sci; 2006 Nov; 95(11):2543-52. PubMed ID: 16937336
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of verproside after intravenous and oral administration in rats.
Park EJ; Lee HS; Oh SR; Lee HK; Lee HS
Arch Pharm Res; 2009 Apr; 32(4):559-64. PubMed ID: 19407974
[TBL] [Abstract][Full Text] [Related]
13. Hepatic and intestinal first-pass effects of a new hepatoprotective agent, YH439, in rats.
Kim J; Han KS; Lee JW; Lee MG
Res Commun Mol Pathol Pharmacol; 1998 Nov; 102(2):125-36. PubMed ID: 10100504
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Shim HJ; Kim YC; Park KJ; Kim DS; Kwon JW; Kim WB; Lee MG
J Pharm Sci; 2003 Nov; 92(11):2185-95. PubMed ID: 14603504
[TBL] [Abstract][Full Text] [Related]
15. Dose-independent pharmacokinetics of a candidate for diabetic neuropathy, SR-4668, after intravenous and oral administration to rats: Intestinal first-pass effect.
Kim EJ; Bae SK; Kim HJ; Kim YG; Kim SO; Lee DH; Lim H; Lee MG
J Pharm Sci; 2003 May; 92(5):1112-24. PubMed ID: 12712431
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and first-pass metabolism of astaxanthin in rats.
Choi HD; Kang HE; Yang SH; Lee MG; Shin WG
Br J Nutr; 2011 Jan; 105(2):220-7. PubMed ID: 20819240
[TBL] [Abstract][Full Text] [Related]
17. Dose-dependent pharmacokinetics and first-pass effects of mirodenafil, a new erectogenic, in rats.
Choi YH; Lee YS; Bae SH; Kim TK; Lee BY; Lee MG
Biopharm Drug Dispos; 2009 Sep; 30(6):305-17. PubMed ID: 19639551
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and first-pass effects of liquiritigenin in rats: low bioavailability is primarily due to extensive gastrointestinal first-pass effect.
Kang HE; Cho YK; Jung HY; Choi KY; Sohn SI; Baek SR; Lee MG
Xenobiotica; 2009 Jun; 39(6):465-75. PubMed ID: 19480552
[TBL] [Abstract][Full Text] [Related]
19. Dose-independent pharmacokinetics of a new neuroprotective agent for ischemia-reperfusion damage, KR-31543, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects.
Lee MH; Bae SK; Kim EJ; Kim YG; Kim SO; Lee DH; Lim H; Yoo SE; Lee MG
J Pharm Sci; 2003 Jan; 92(1):190-201. PubMed ID: 12486695
[TBL] [Abstract][Full Text] [Related]
20. Clindamycin bioavailability and pharmacokinetics following oral administration of clindamycin hydrochloride capsules in dogs.
Batzias GC; Delis GA; Athanasiou LV
Vet J; 2005 Nov; 170(3):339-45. PubMed ID: 16266847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
